327.19

0.12% 0.39

Insulet Corporation (PODD)

Overview News Price History Option Chain Financials Why PODD Down? Discussions Forecast

Insulet Corporation stock is traded at $327.19, with a volume of 224.66K. It is up +0.12% in the last 24 hours and up +0.88% over the past month. Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Previous Close:

$326.80

Open:

$327.95

24h Volume:

224.66K

Relative Volume:

0.36

Market Cap:

$23.02B

Revenue:

$2.36B

Net Income/Loss:

$236.10M

P/E Ratio:

99.57

EPS:

3.286

Net Cash Flow:

$382.50M

1W Performance:

-1.20%

1M Performance:

+0.88%

6M Performance:

+1.13%

1Y Performance:

+22.58%

1-Day Range:

$324.28

$328.28

1-Week Range:

$324.00

$342.13

52-Week Range:

$230.05

$354.88

Insulet Corporation Stock (PODD) Company Profile

Name

Insulet Corporation

Sector

Healthcare (1139)

Industry

Medical Devices (144)

Phone

978-600-7000

Address

100 NAGOG PARK, ACTON, MA

Employee

3,900

Twitter

@insulet_uk

Next Earnings Date

2024-11-07

Latest SEC Filings

PODD's Discussions on Twitter

Compare PODD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PODD Insulet Corporation	327.19	22.99B	2.36B	236.10M	382.50M	3.286
ABT Abbott Laboratories	128.90	223.51B	43.84B	13.90B	6.92B	7.9725
BSX Boston Scientific Corp	101.58	149.67B	19.35B	2.78B	3.82B	1.8696
SYK Stryker Corp	371.18	142.37B	24.38B	2.94B	4.07B	7.6159
MDT Medtronic Plc	105.33	134.64B	34.76B	4.79B	5.21B	3.7017
EW Edwards Lifesciences Corp	86.67	50.34B	5.88B	1.34B	799.60M	2.3489

Insulet Corporation Stock (PODD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-19-25	Upgrade	UBS	Neutral → Buy
Oct-21-25	Resumed	Stifel	Buy
Sep-08-25	Resumed	Oppenheimer	Outperform
Jun-16-25	Initiated	Truist	Buy
May-30-25	Initiated	Goldman	Buy
May-13-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Apr-29-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Mar-06-25	Initiated	RBC Capital Mkts	Outperform
Nov-06-24	Initiated	Bernstein	Outperform
May-30-24	Initiated	Redburn Atlantic	Buy
May-07-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Dec-21-23	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-04-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-02-23	Upgrade	Jefferies	Hold → Buy
Aug-21-23	Upgrade	Citigroup	Neutral → Buy
Aug-21-23	Downgrade	Robert W. Baird	Outperform → Neutral
May-30-23	Resumed	Morgan Stanley	Equal-Weight
Jan-26-23	Initiated	Wolfe Research	Peer Perform
Nov-04-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-18-22	Initiated	Barclays	Equal Weight
Oct-12-22	Initiated	Jefferies	Hold
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Buy
Feb-03-22	Upgrade	BTIG Research	Neutral → Buy
Feb-02-22	Upgrade	UBS	Neutral → Buy
Jan-31-22	Upgrade	Oppenheimer	Perform → Outperform
Jul-21-21	Resumed	Cowen	Outperform
May-25-21	Initiated	Barclays	Overweight
Apr-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-19-21	Upgrade	Canaccord Genuity	Hold → Buy
Jan-29-21	Downgrade	Piper Sandler	Overweight → Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Jul-28-20	Initiated	Wells Fargo	Overweight
Apr-24-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-03-20	Initiated	BofA/Merrill	Neutral
Mar-31-20	Downgrade	Berenberg	Buy → Hold
Mar-05-20	Initiated	Citigroup	Buy
Dec-10-19	Initiated	CFRA	Sell
Oct-23-19	Initiated	Stifel	Hold
Oct-18-19	Downgrade	Canaccord Genuity	Buy → Hold
Oct-14-19	Downgrade	BTIG Research	Buy → Neutral
Oct-04-19	Downgrade	UBS	Buy → Neutral
Oct-03-19	Downgrade	Guggenheim	Buy → Neutral
Aug-06-19	Upgrade	JP Morgan	Neutral → Overweight
Jun-10-19	Downgrade	Northland Capital	Outperform → Market Perform
May-06-19	Upgrade	BTIG Research	Neutral → Buy
Apr-20-18	Initiated	Berenberg	Buy
Feb-22-18	Reiterated	Barclays	Overweight
Jan-08-18	Upgrade	Raymond James	Mkt Perform → Outperform
Nov-03-17	Upgrade	Canaccord Genuity	Hold → Buy
Sep-15-17	Initiated	Barclays	Overweight

View All

Insulet Corporation Stock (PODD) Latest News

Nov 27, 2025

Treasury Yields: Why Insulet Corporation (GOV) stock is a strong analyst pickEarnings Recap Report & Real-Time Volume Surge Alerts - moha.gov.vn

Nov 27, 2025

Nov 26, 2025

Diabetes Dialogue: Upcoming Upgrades for Omnipod Technology - HCPLive

Nov 26, 2025

Nov 25, 2025

How Insulet’s (PODD) New Omnipod Roadmap and Growth Targets Are Shaping Its Investment Story - simplywall.st

Nov 25, 2025

Insulet (PODD)'s True Value: Is It Overpriced? An In-Depth Explo - GuruFocus

Nov 25, 2025

Nov 24, 2025

Canaccord Genuity raises Insulet stock price target to $432 on growth plan - Investing.com Nigeria

Nov 24, 2025